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Abstract
Background: There is some evidence to support a risk-stratified, multi-disciplinary approach to manage patients
with hypertension in primary care. The aim of this study is to evaluate the quality of care (QOC) of a multi-
disciplinary Risk Assessment and Management Programme for Hypertension (RAMP-HT) for hypertensive patients in
busy government-funded primary care clinics in Hong Kong. The objectives are to develop an evidence-based,
structured and comprehensive evaluation framework on quality of care, to enhance the QOC of the RAMP-HT
through an audit spiral of two evaluation cycles and to determine the effectiveness of the programme in reducing
cardiovascular disease (CVD) risk.
Method/Design: A longitudinal study is conducted using the Action Learning and Audit Spiral methodologies to
measure whether pre-set target standards of care intended by the RAMP-HT are achieved. A structured evaluation
framework on the quality of structure, process and outcomes of care has been developed based on the programme
objectives and literature review in collaboration with the programme workgroup and health service providers. Each
participating clinic is invited to complete a structure of care evaluation questionnaire in each evaluation cycle. The
data of all patients who have enrolled into the RAMP-HT in the pre-defined evaluation periods are used for the
evaluation of the process and outcomes of care in each evaluation cycle. For evaluation of the effectiveness of
RAMP-HT, the primary outcomes including blood pressure (both systolic and diastolic), low-density lipoprotein
cholesterol and estimated 10-year CVD risk of RAMP-HT participants are compared to those of hypertensive patients
in usual care without RAMP-HT.
Discussion: The QOC and effectiveness of the RAMP-HT in improving clinical and patient-reported outcomes for
patients with hypertension in normal primary care will be determined. Possible areas for quality enhancement and
standards of good practice will be established to inform service planning and policy decision making.
Keywords: Hypertension, Management programme, Multi-disciplinary, Primary Care, Quality of care, Risk
Assessment, Risk Stratification
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Background
Hypertension (HT) is a global public health issue and an
important risk factor for coronary heart diseases, cere-
brovascular diseases and renal failure [1, 2]. In Hong
Kong, the condition affects 27.2 % of people aged over
15 years and more than 65 % of elderly [3]. Approxi-
mately 200,000 people with HT are currently receiving
care at government-funded primary care clinics (i.e.
General Outpatient Clinics (GOPC) operated by the
Hospital Authority (HA)). The majority of these GOPC
attendants are elderly. With the threat of aging popula-
tion and the foreseeable increase in demand of public
primary health services to provide chronic disease care,
a sustainable and effective management programme to
improve the quality of care for HT and to lessen public
healthcare burden deems a good solution.
Assessment of total cardiovascular risk has been advo-
cated internationally as a holistic and cost-effective way
to guide intervention for patients with HT, where re-
sources can be directed to patients with highest risk in
order to achieve maximal prevention or reduction in
cardiovascular diseases (CVD) and mortalities [2, 4–6].
The Ontario Medical Association found that compre-
hensive screening and management via stratification of
risk factors in hypertensive patients could double the re-
duction in cardiovascular risk, lower the blood pressure
and change the types of antihypertensive medications
recommended [7–9]. The Joint British Societies (JBS)
recommended prediction of the total risk of developing
cardiovascular diseases (i.e. coronary heart disease plus
stroke) over 10 years based on five risk factors: age, gen-
der, smoking habit, systolic blood pressure, and the ratio
of total cholesterol to HDL-cholesterol, modified from
the original Framingham equations, to guide interven-
tion and treatment targets [4]. However, no similar risk-
stratification-risk-management programme for patients
with HT had been established among Chinese.
The Risk Assessment and Management Programme–
Hypertension (RAMP-HT) is an evidence-based [2, 4, 10],
structured, protocol-driven multidisciplinary management
programme launched by the HA in October 2011 to im-
prove the quality of care (QOC) for HT patients in the
public primary care setting. Hypertensive patients receiv-
ing care from GOPC, especially those who have subopti-
mal blood pressure control above 140/90 mmHg, are
recruited. Standardized cardiovascular risk factor assess-
ment, hypertensive complication screening and assess-
ment on adherence to treatment are carried out on
enrolled patients (Additional file 1). Patients are stratified
into low, medium or high risk groups according to the 10-
year cardiovascular disease (CVD) risk calculated from
their relevant risk factors by the JBS 2005 Equation. A
multi-disciplinary team comprised of doctors, nurses,
dietitians, physiotherapist and/or occupational therapists
then deliver individualized management targeted to the
patient’s risk factors according to standardized risk-
stratified guidelines (Additional file 2).
In order to facilitate the operation of RAMP-HTas an in-
tegrated component to usual GOPC care but not a stand-
alone programme, multi-level organizational changes had
been made. Patient assessment and education were dele-
gated from frontline doctors to trained nurses and allied
health professionals. A risk-guided management protocol
was used to guide doctors and nurses regarding drug
choices and referrals. A new clinical data entry platform
was built to enhance relay of information between frontline
doctors and other healthcare providers. These various strat-
egies had all previously been proven to improve HT care
[11], but few programmes incorporated as much changes
and to such a scale [12–15].
The evaluation of QOC and effectiveness is an essen-
tial part of any chronic disease management programme
in order to assure that the intended care is provided and
whether a health benefit can be gained. The information
will inform future policy and service planning. There-
fore, we aim to evaluate the QOC and effectiveness of
the RAMP-HT to prove if such approach of HT man-
agement can be implemented and beneficial in the nat-
uralistic busy primary health care setting.
Aims and objectives
The aim of this study is to evaluate the quality of care
(QOC) and effectiveness of the multi-disciplinary Risk
Assessment and Management Programme for Hyperten-
sion (RAMP-HT) for patients with HT managed by
government-funded primary care clinics in Hong Kong.
The evaluation is conducted using a structured and
comprehensive evidence-based evaluation framework.
The objectives of the study are:
1. To review and identify the structure, process and
outcome indicators of quality of care;
2. To identify the criterion and set the target standard
for each indicator;
3. To compare the observed standards against the
target standards;
4. To identify any on-site problems related to
implementation of the RAMP-HT;
5. To provide feedback on the quality of care of the
RAMP-HT;
6. To identify possible areas for improvement;
7. To give recommendations for enhancement of
service delivery
The following hypotheses will be tested:
1. The structure and process criteria of care should be
achieved up to standards by all participating clinics;
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2. A higher proportion of patients should have
achieved the target blood pressure and low density
lipoprotein cholesterol (LDL-C) level after the
RAMP-HT;
3. There should be a reduction in the predicted 10-year
CVD risk 12 and 24 months after RAMP-HT;
4. Patients who have participated in the RAMP-HT
should have better clinical outcomes than patients
managed by usual-care (control);
5. RAMP-HT is associated with a lower incidence of
cardiovascular diseases in the long term.
Methods/Design
Evaluation of quality of care
A longitudinal study using the Action Learning [16] and
Audit Spiral methodologies [17] is conducted for a sys-
tematic analysis of the QOC and to identify areas for en-
hancement for the RAMP-HT. Two evaluation cycles
are carried out with feedback of results and a quality en-
hancement action plan has been implemented after the
first evaluation, aiming at a higher level of quality of care
at the second cycle. Interim site visits are conducted to
identify any problems of on-site implantation of the
programme.
Development of the evaluation framework
Donabedian’s taxonomy of QOC on structure, processes
and outcomes is used as the base of the evaluation
framework [18]. A QOC framework has been developed
by an iterative process and reconciliation between the
investigators and the programme providers (Fig. 1). An
intensive literature review on HT is first conducted to
identify key elements of qualitied HT management in
primary care. The investigators then work together with
the programme providers (HA RAMP-HT Workgroup),
frontline practitioners (HA doctors and nurses repre-
sentatives) and the Statistics and Workforce Planning
Department of the HA (HA statistics team) to discuss
on which aspects need to be evaluated and what data
are retrievable from the computer system. This final
evaluation framework lists out the indicators of the
structure (staff, facilities, organization and management),
process (what, when and how care is delivered) and out-
comes (clinical outcomes and patient reported out-
comes) with the required criteria and standard of care
to be achieved (Additional file 3).
Subjects
All hypertensive patients without diabetes mellitus who are
managed under the HA GOPC are referred from doctors
and nurses to participate in the programme. Before enrol-
ment to RAMP-HT, eligibility screening is performed to
identify eligible patients based on the following inclusion
and exclusion criteria: Inclusion criteria are patients who
are diagnosed with hypertension and regularly followed
up in GOPC; Patients are excluded if they are diagnosed
with diabetes mellitus; they will be enrolled into another
risk-stratification and management programme for dia-
betic patients. The priority of enrolment is reserved for
patients who have suboptimal blood pressure control
above 140/90 mmHg.
All patients enrolled into the RAMP-HT are included in
the evaluation on process and clinical outcome of care for
each evaluation cycle. To determine the clinical effective-
ness of RAMP-HT, a matched control study is performed
to compare RAMP-HT participants to matched HT pa-
tients receiving usual GOPC care who have not partici-
pated in the RAMP-HT. The same number of RAMP-HT
participants and age-sex-disease severity-matched usual
care HT patients are randomly selected. Disease severity is
defined by the presence or absence of end-organ damages,
disease control (baseline blood pressure level) and required
treatment. It is not feasible to control for all co-morbidities
but these will be examined as possible confounding factors
in the data analysis.
A total of 600 patients, 300 RAMP-HT participants
and 300 usual care HT patients, are recruited from
GOPC by trained research assistants for a telephone sur-
vey on patient reported outcomes (PRO). All subjects
who have given consent to the telephone follow-up sur-
vey are interviewed by telephone within 4 weeks and at
12 months from recruitment.
Sample size calculation
To determine a difference between groups (RAMP-HT
participants and usual-care group), proportions of 5 % in
achieving the target clinical outcomes (blood pressure <
140/90 mmHg) with 80 % power and 95 % confidence
interval, 1248 subjects are needed in each group [19].
Thus, a minimum of 1248 RAMP participants and 1248
controls has to be included in the evaluation of out-
comes after 1 year.
The sample size for the evaluation of PRO score change
after RAMP-HT is estimated to detect a minimally clinic-
ally important difference (MCID) that is equivalent to
Cohen’s small effect size of 0.3 [20]. A sample size of 176
subjects in each group is required to have 80 % power and
95 % confidence interval to detect the expected difference
by independent t-test [21]. Therefore, 300 patients in each
group, i.e. a total of 600, have to be recruited to account
for a maximum of 40 % dropouts.
Data collection
Evaluation on structure and process
The coordinator of each participating HA cluster and
clinic are asked to complete a structure of care question-
naire (Additional file 4). Provider characteristics are also
collected. In addition to the self-assessment, we ask the
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provider to submit a list of the staff and facilities desig-
nated for the programme, and a description of the
programme objectives and protocol. We also carry out
site visits to cross-validate the data.
Anonymized data are retrieved from the computerized
medical record system (CMS) by the HA statistics team
to determine the patient recruitment rate, enrolment
rate, risk stratification, attendance at RAMP-HT clinic,
compliance with assessment and care per programme
protocol, investigations and referral rates.
Evaluation on outcomes of care
Anonymized data of on the relevant clinical outcomes
(e.g. blood pressure, LDL-C) of RAMP-HT subjects and
selected usual-care comparison group at baseline, 12
and 24 months from enrolment are retrieved from the
CMS by the HA statistics team. The 10-year predicted
CVD risk of the RAMP-HT subjects and usual care
groups recruited in both cycles is estimated base on the
clinical parameters at 12 and 24 months from enrolment
to evaluate the effectiveness of the programme in the re-
duction of predicted CVD risk.
RAMP-HT participants and usual care HT patients who
have agreed to the PRO survey are interviewed by tele-
phone by trained interviewers of the HKU Social Science
Research Centre within 1 and at 12 months from enrol-
ment to answer the Short Form-12 version 2 (SF-12v2)
Health Survey on health-related quality of life (HRQOL),
the Patient Enablement Instrument (PEI) and Global
Rating of Change Scale (GRS) to detect change in health
Fig. 1 An iterative process and reconciliation between the investigators and the programme providers
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and a structured questionnaire on life-style measures and
knowledge on hypertension (Additional file 5).
Two audit and feedback cycles
Two evaluation (audit) cycles on the standards of care
are carried out at 24 months (September, 2013) and
48 months (September, 2015) from the start of the
RAMP-HT programme. The first evaluation cycle in-
cludes subjects who are enrolled between October 2011
and March 2012 to evaluate the process of care and
12-month clinical outcomes at the start of the programme.
The results have been fed back to the HA programme
team to identify quality gaps and possible quality enhance-
ment strategies. A revised QOC evaluation framework is
developed for the second evaluation cycle based on new
agreed indicators and target standards. The second evalu-
ation cycle includes subjects enrolled into the RAMP-HT
from January to June, 2014 to determine the standards
that are achievable after the programme has been estab-
lished. The results of second evaluation cycle will also be
fed back to the programme team to identify any future
areas for improvement of RAMP-HT.
Outcome measures
Primary
1. The proportion of clinics that have satisfied each of
the structure of care criteria.
2. The number and proportion of HT patients who
have completed RAMP-HT.
3. The proportion of patients who have complied with
the process of care criteria.
4. The proportion of patients who have achieved
BP < 140/90 mmHg.
5. HT-related complication rates, e.g. coronary heart
disease, cerebrovascular diseases, all-cause
mortality, etc.
Secondary
1. Mean change in blood pressure, LDL-C level at
12 months
2. The predicted 10-year cardiovascular disease risk
level stratified by RAMP-HT and 2008 Framingham
prediction function at 12 and 24 months
3. Patient reported outcomes (PRO) measured by the
change in SF-12v2 scores, the PEI and GRS scores at
12 months
Study instruments
Study instruments are used in evaluating the structure
of care and the PRO. Evaluation of the process of care
and outcomes do not involve use of study instruments
as the necessary data are retrieved from the HA through
the Statistics and Workforce Planning Department.
Structure of care questionnaire
Structure of care questionnaire is sent to the cluster co-
ordinators and clinic doctors-in-charge of the RAMP-
HT and requires their input. The questionnaire covers
questions on resources spent on RAMP-HT, e.g. whether
there is enough physical space and staff training for the
programme, whether there is a data sharing platform
within the programme, etc.
Three study instruments are used in the evaluation of
the PRO, namely the short form-12 version 2 Health
Survey, the Patient Enablement Instrument, and the
Global Rating of Change Scale.
A. The Short Form-12 version 2 (SF-12v2) Health
Survey. The Chinese (Hong Kong) SF-12v2 Health
Survey is used to measure HRQOL. It has been
validated [22] and normed [23] on the general
Chinese population in Hong Kong. It measures eight
domains of HRQOL on physical functioning, role
physical, bodily pain, general health, vitality, social
functioning, role emotional and mental health on a
scale range from 0 to 100. A higher score indicates
better HRQOL. The eight domain scores are
aggregated into two summary scores, the physical
(PCS) and mental (MCS) component summary.
B. The Patient Enablement Instrument (PEI). The PEI
is a measure of patient’s enablement in coping with
the illness and life [24]. It has 6 items each rated on
a 3-point (0, 1, and 2) scale. The summation of the
item scores gives the PEI score with a higher score
indicating better enablement. The PEI has been
translated into Chinese and is shown to be valid and
reliable in Chinese patients in primary care [25].
C. The Global Rating of Change Scale (GRS). The GRS
is adapted from those used in studies by Jaeschke
and Osoba et al. [26]. It assesses the subject’s global
perception of any change in the overall health
condition on a 7-point scale (−3, −2, −1, 0, 1, 2, and
3) over the last 6 months.
Data analysis
Descriptive statistics on standards of care are calculated
by the percentage of clinics meeting the structure cri-
teria, percentage of subjects enrolled, attendance and
completion of the programme, receiving criterion
process of intervention, investigations and referral per
protocol and percentage of subjects achieving the criter-
ion outcomes in each audit cycle. Cardiovascular risk
analysis is performed by the Joint British Societies’ and
the 2008 Framingham cardiovascular disease risk predic-
tion functions. These equations predict the 10-year total
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risk of fatal and non-fatal CHD/CVD events and are ap-
plicable to patients aged 30–74 years. Within subject im-
provement in outcomes from baseline at 12 and at
24 months is analysed by paired t-test for continuous
outcomes and McNemar test for binary outcomes. Dif-
ferences in outcomes between RAMP-HT participants
and usual-care group, between audit cycles are tested by
analysis of variance (ANOVA) for continuous outcomes
and Chi-squared tests for categorical outcomes. Self-
selection biases are examined over inter-subject and inter-
group differences by analysis of covariance. Multiple re-
gressions are used to identify factors that are associated
with quality of care or effectiveness.
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Discussion
The multi-disciplinary RAMP-HT is a territory-wide
quality improvement (QI) programme initiated by the
Hospital Authority of Hong Kong to enhance HT care in
the public primary care setting, which manages over
50 % of all HT patients in Hong Kong (according to HA
internal data). This evaluation study differs from previ-
ous studies in that it is carried out in the naturalistic
busy public primary care setting and is much larger in
scale, which makes the results more valid and reliable. A
participatory-action-research design is now recognized
to be the most effective way to evaluate the quality of
care of such a complex systematic intervention in the
naturalistic clinical setting [27]. We engage all key stake-
holders including frontline healthcare providers and the
HA programme administrators right from the beginning
to agree on the quality criteria and target standards and
review the evaluation results in order to identify possible
areas for quality enhancement and standards of good
practice. The various parties are motivated to make
changes in response to new evaluation evidence that
emerges during the study process.
A similar evaluation study on Risk Assessment and
Management Programme (RAMP) for diabetic patients
was carried out in Hong Kong [28]. Fung et al. highlighted
different practical aspects for conducting this type of
action-research, namely coordination of stakeholder col-
laboration and communication, regular feedback and
planning meetings, stakeholder endorsement and valid-
ation for the evaluation framework and operation defini-
tions and ensuring data quality, which are also applicable
to our RAMP-HT QOC evaluation.
The first evaluation cycle of our study has been com-
pleted in 2014. From our experience, the major chal-
lenges in this evaluation of quality of care study are:
1. Operational definitions of indicators of the
evaluation framework
Although indicators and criteria of qualitied HT
care are well-documented in the literature and
recommended in international and local management
guidelines, we discovered variations in operational
definitions among service providers. We have now
agreed among all stakeholders on the explicit
definitions of “blood pressure control” (i.e. averaged
blood pressure readings over 6 months) and “target
organ damage” (i.e. only left ventricular hypertrophy
and stage 3 or above chronic kidney disease were
included based on available data sources). The
assessment methods for different target organ
damages and cardiovascular complications (e.g.
peripheral vascular disease) were found to vary
across participating clinics, standardization on how
to determine the presence of these conditions was
essential. Some required clinical indicators were not
captured systematically by existing data collection
platform (e.g. presence of proteinuria by urine
dipstick, ischaemic changes in the electrocardiogram)
and thus could not be accurately evaluated, and
our research team has to work with the frontline
healthcare providers and programme administrators
to decide on the best practices that are applicable
and acceptable in the local setting.
Setting appropriate target standard for each of the
criterion in the evaluation framework is also
important; there should be a balance between the
ideal (normative) and what is practical (empirical) in
the real life clinical setting. The standard needs to be
set high enough to motivate quality improvement
but low enough to be achievable.
2. Ensuring protocol adherence and data quality
For evaluation of the quality of care, anonymized
data on the processes and clinical outcomes of care
are extracted from the Hospital Authority’s
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information system retrospectively. In order to
cross-validate the accuracy of the data, it is essential to
monitor the steps of which these data are generated.
Site visits to different participating clinics to
observe real-life practices have proven to be most
informative. For instance, our team noticed that
different definitions (pre-treatment versus post-treatment
blood pressure or cholesterol levels) were used by
frontline staff for CVD risk calculation; this issue
was fed back to the RAMP-HT workgroup, leading
to a consensus on using the pre-treatment levels.
On the other hand, other variations such as staff
or mode of patient education were considered
acceptable because the same RAMP-HT operation
principles were maintained.
The key to successful implementation of our evalu-
ation study is the mutual trust among different partners
being built up through open feedback and discussions.
During an evaluation exercise, conflict of interest is inev-
itable: health policy decision makers concern about allo-
cation of resources, programme administrators focus on
service outcome while frontline healthcare providers
may perceive it as an additional burden to their busy
work. It is important to stress frequently that the ultim-
ate collective aim of the study is quality improvement
but not fault-finding. In addition, open channel communi-
cation is essential to allow adequate, effective discussions
of concerns and practical difficulties among various par-
ties. A good representation of key stakeholders consisting
of frontline healthcare providers, programme planner and
researchers must be included in the study workgroup who
meet regularly throughout the study process from plan-
ning, implementing quality improvement strategies and
dissemination of results.
Conclusion
With the increasing numbers of patients with hypertension,
a well-organized and comprehensive multi-disciplinary ap-
proach to care is the future direction of healthcare delivery.
Proper evaluation is required to assure whether RAMP-HT
can serve this purpose in real practice, and to provide evi-
dence on its likely health benefit for the patients.
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Additional file 4: RAMP-HT structure of care questionnaire.
Additional file 5: RAMP-HT patient reported outcomes
questionnaire.
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